JP2011079866A5 - - Google Patents

Download PDF

Info

Publication number
JP2011079866A5
JP2011079866A5 JP2011011407A JP2011011407A JP2011079866A5 JP 2011079866 A5 JP2011079866 A5 JP 2011079866A5 JP 2011011407 A JP2011011407 A JP 2011011407A JP 2011011407 A JP2011011407 A JP 2011011407A JP 2011079866 A5 JP2011079866 A5 JP 2011079866A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
following formula
aryl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011011407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011079866A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011079866A publication Critical patent/JP2011079866A/ja
Publication of JP2011079866A5 publication Critical patent/JP2011079866A5/ja
Pending legal-status Critical Current

Links

JP2011011407A 2004-03-22 2011-01-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター Pending JP2011079866A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55538004P 2004-03-22 2004-03-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007505043A Division JP2007530546A (ja) 2004-03-22 2005-03-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター

Publications (2)

Publication Number Publication Date
JP2011079866A JP2011079866A (ja) 2011-04-21
JP2011079866A5 true JP2011079866A5 (enExample) 2012-02-16

Family

ID=34963517

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007505043A Pending JP2007530546A (ja) 2004-03-22 2005-03-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター
JP2011011407A Pending JP2011079866A (ja) 2004-03-22 2011-01-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007505043A Pending JP2007530546A (ja) 2004-03-22 2005-03-21 マトリックスメタロプロテイナーゼの非ペプチドインヒビター

Country Status (17)

Country Link
US (1) US8129406B2 (enExample)
EP (1) EP1735274B1 (enExample)
JP (2) JP2007530546A (enExample)
KR (1) KR20070046025A (enExample)
CN (1) CN101001834B (enExample)
AT (1) ATE449760T1 (enExample)
AU (1) AU2005227311B2 (enExample)
CA (1) CA2560739A1 (enExample)
DE (1) DE602005017879D1 (enExample)
DK (1) DK1735274T3 (enExample)
ES (1) ES2338243T3 (enExample)
MX (1) MXPA06010974A (enExample)
NZ (1) NZ550621A (enExample)
PL (1) PL1735274T3 (enExample)
PT (1) PT1735274E (enExample)
SI (1) SI1735274T1 (enExample)
WO (1) WO2005092844A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008338631A1 (en) 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
WO2010047803A2 (en) * 2008-10-22 2010-04-29 Oncotx, L.L.C. A method for the treatment of proliferative disorders of the eye

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
SK282863B6 (sk) * 1996-05-17 2002-12-03 Warner-Lambert Company Bifenylsulfonamidy, ich použitie a farmaceutické prostriedky na ich báze
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
US5977408A (en) 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
KR20000049198A (ko) 1996-10-16 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로티나아제 및 tace 억제제로서의 베타-설폰아미도 하이드록스암산
CN1254337A (zh) * 1997-03-04 2000-05-24 孟山都公司 N-羟基4-磺酰基丁酰胺化合物
GB9708133D0 (en) 1997-04-22 1997-06-11 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
US6326516B1 (en) * 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR035478A1 (es) * 1999-01-27 2004-06-02 Wyeth Corp Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene
AUPP982399A0 (en) 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
EP1355648A2 (en) * 2001-01-11 2003-10-29 Bristol-Myers Squibb Pharma Company 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)

Similar Documents

Publication Publication Date Title
JP2013032389A5 (enExample)
JP2014500861A5 (enExample)
JP2010095546A5 (enExample)
JP2011518833A5 (enExample)
JP2013532687A5 (enExample)
JP2011105738A5 (enExample)
JP2013518107A5 (enExample)
JP2012092103A5 (enExample)
JP2010501534A5 (enExample)
JP2009535462A5 (enExample)
JP2013537203A5 (enExample)
JP2013521295A5 (enExample)
JP2011513410A5 (enExample)
JP2017537066A5 (enExample)
JP2014515013A5 (enExample)
JP2016514159A5 (enExample)
JP2013512915A5 (enExample)
JP2015537020A5 (enExample)
JP2009143956A5 (enExample)
JP2015502963A5 (enExample)
JP2009545527A5 (enExample)
JP2015512931A5 (enExample)
JP2014508811A5 (enExample)
JP2009149903A5 (enExample)
JP2010536766A5 (enExample)